When was QurAlis founded?

QurAlis was founded in 2016 and raised its 1st funding round 2 years after it was founded.

Where is QurAlis located?

QurAlis is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

Who is the current CEO of QurAlis?

Kasper Roet of QurAlis. They have also founded 1 company.

How many employees does QurAlis have?

As of Jul 31, 2026, the latest employee count at QurAlis is 77.

Is QurAlis a funded company?

QurAlis is a funded company, having raised a total of $155M across 7 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Apr 05, 2018.

When was the latest funding round of QurAlis?

QurAlis' latest funding was a $***** Series B round on Aug 21, 2025, with participation from 0 investor.

Where does QurAlis rank among its competitors?

QurAlis ranks 31st amongst 604 active competitors, of which 213 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was QurAlis, which secured $20M in Aug, 2025.

Who are the top competitors of QurAlis?

QurAlis' top competitors include Alnylam, Spark Therapeutics and Strand Therapeutics. Among them, QurAlis secured the most recent funding round in August, 2025.

QurAlis - 2026 Company Profile, Team, Funding & Competitors

QurAlis is a series B company based in Cambridge (United States), founded in 2016 by Kevin Eggan and Kasper Roet. It operates as a Developing drugs & CSF cartridge device for treating amyotrophic lateral sclerosis (ALS). QurAlis has raised $155M in funding from investors like Polaris Partners, BioInnovation Capital and MP Healthcare Venture Management. The company has 604 active competitors, including 213 funded and 141 that have exited. Its top competitors include companies like Alnylam, Spark Therapeutics and Strand Therapeutics.

Company Details

QurAlis is engaged in discovering and developing new therapies for amyotrophic lateral sclerosis (ALS), which is a common form of motor neuron disease. The company has developed Optopatch technology which helps in stimulating the neurons and notes their electrical behavior. Their proprietary method clears toxic proteins and transcranial magnetic stimulation helps in diagnosing ALS by identifying biomarkers such as protein in the blood. In addition, other therapeutic targets like nerve threshold tracking, proteins in the cerebral spinal fluid helps to predict ALS. The company has a preclinical-stage program for ALS drugs targeting the Kv7.2/7.3 channel & CSF cartridge device to remove DPR proteins.

Website: quralis.com
Social
Email ID: *****@quralis.com
Phone Number: +1 **********
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

2016

Location

Cambridge, United States

Stage

Series B

Total Funding

$155M in 7 rounds

Latest Funding Round

Series B, Aug 21, 2025, $*****

Investors

Polaris Partners & 22 more

Ranked

31^st among 604 active competitors

Employee Count

77 as on Jul 31, 2026

Similar Companies

Alnylam & 748 more

View QurAlis' full profile

QurAlis is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
QURALIS CORPORATION CIN: 814722156 , United States, Active	Dec 11, 2016	-	55 (As on Dec 31, 2024)	-

QurAlis has raised a total funding of $155M over 7 rounds. Its first funding round was on Apr 05, 2018. QurAlis has 23 institutional investors.

Here is the list of recent funding rounds of QurAlis:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 21, 2025	8792151	Series B	7854306	6532492	2389308	1758103
Mar 09, 2023	7706483	Series B	3325385	4508966	6060086	Life Sciences Partners & 10 more
Sep 30, 2022	4140667	Grant (prize money)	6670246	7264166	3557475	HHS

Access funding benchmarks and valuations. Sign up today!

View details of QurAlis's funding rounds and investors

The founders of QurAlis are Kevin Eggan and Kasper Roet. Kasper Roet is the CEO of QurAlis.

Here are the details of QurAlis' key team members:

Kevin Eggan: Founder of QurAlis and founder of 1 other company.
Contact Info: 1 email address
Kasper Roet: Founder & CEO of QurAlis.

View details of QurAlis's Founder profiles and Board Members

QurAlis' employee count trend

QurAlis has 77 employees as of Jul 26. Here is QurAlis's employee count trend over the years:

Uncover QurAlis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of QurAlis include Alnylam, Spark Therapeutics and Strand Therapeutics. Here is the list of Top 10 competitors of QurAlis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Bellevue Healthcare Trust ... & 13 others	79/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
3rd	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	70/100
4th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, Xontogeny & 7 others	70/100
5th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
6th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
7th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	Adage Capital Management, F-Prime Capital ... & 10 others	69/100
8th	Generation Bio 2016, Cambridge (United States), Acquired	Developer of gene therapies for rare liver and eye diseases	$236M	Fidelity Investments, T. Rowe Price & 9 others	69/100
9th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Matrix Capital Management, EDBI & 16 others	68/100
10th	Krystal Biotech 2015, Pittsburgh (United States), Public	Developer of genetic medicines to treat rare diseases	$11.3M	Frazier Life Sciences, Danforth Advisors & 2 others	67/100
31st	QurAlis 2016, Cambridge (United States), Series B	Developing drugs & CSF cartridge device for treating amyotrophic lateral sclerosis (ALS)	$155M	Amgen Business Development, Life Sciences Partners ... & 21 others	63/100